MX2016014615A - Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes. - Google Patents
Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes.Info
- Publication number
- MX2016014615A MX2016014615A MX2016014615A MX2016014615A MX2016014615A MX 2016014615 A MX2016014615 A MX 2016014615A MX 2016014615 A MX2016014615 A MX 2016014615A MX 2016014615 A MX2016014615 A MX 2016014615A MX 2016014615 A MX2016014615 A MX 2016014615A
- Authority
- MX
- Mexico
- Prior art keywords
- imaging agents
- heterocyclic compounds
- salts
- compounds
- deuterated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Optics & Photonics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención se refiere a compuestos deuterados y etiquetados detectables opcionalmente de la fórmula (I): R1-A-R2 y de la fórmula (V) y las sales de los mismos, en donde R1, R2, A y X10-X19 tienen cualquiera de los valores definidos en la especificación. También se incluyen las composiciones farmacéuticas que comprenden tales compuestos y las sales, y los métodos de uso de tales compuestos y las sales como agentes formadores de imágenes, en particular en la medición de la señal radioactiva del compuesto asociado con los depósitos amiloides y/o los agregados de la proteína tau.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461992717P | 2014-05-13 | 2014-05-13 | |
| PCT/EP2015/060447 WO2015173225A1 (en) | 2014-05-13 | 2015-05-12 | Deuterated heterocyclic compounds and their use as imaging agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016014615A true MX2016014615A (es) | 2017-03-06 |
| MX376163B MX376163B (es) | 2025-03-07 |
Family
ID=53269446
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016014615A MX376163B (es) | 2014-05-13 | 2015-05-12 | Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes. |
| MX2020010847A MX384604B (es) | 2014-05-13 | 2015-05-12 | Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020010847A MX384604B (es) | 2014-05-13 | 2015-05-12 | Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes. |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US10076581B2 (es) |
| EP (2) | EP3143011B1 (es) |
| JP (2) | JP6529986B2 (es) |
| KR (2) | KR102530129B1 (es) |
| CN (2) | CN110483522B (es) |
| AU (2) | AU2015261008B2 (es) |
| CA (1) | CA2948721C (es) |
| DK (1) | DK3143011T3 (es) |
| ES (1) | ES2867814T3 (es) |
| HR (1) | HRP20210641T1 (es) |
| HU (1) | HUE053939T2 (es) |
| IL (3) | IL280791B2 (es) |
| LT (1) | LT3143011T (es) |
| MX (2) | MX376163B (es) |
| PL (1) | PL3143011T3 (es) |
| PT (1) | PT3143011T (es) |
| RS (1) | RS61810B1 (es) |
| RU (1) | RU2696492C2 (es) |
| SG (2) | SG11201609281UA (es) |
| SI (1) | SI3143011T1 (es) |
| WO (1) | WO2015173225A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2867814T3 (es) * | 2014-05-13 | 2021-10-20 | Hoffmann La Roche | Compuestos heterocíclicos deuterados y su uso como agentes de formación de imágenes |
| EP3487544A1 (en) | 2016-07-22 | 2019-05-29 | AC Immune S.A. | Compounds for imaging tau protein aggregates |
| EP3487545A1 (en) | 2016-07-22 | 2019-05-29 | AC Immune S.A. | Compounds for imaging tau protein aggregates |
| KR20230127371A (ko) * | 2016-11-01 | 2023-08-31 | 아비나스 오퍼레이션스, 인코포레이티드 | 타우(Tau)-단백질 표적화 프로탁(PROTAC) 및 관련 사용 방법 |
| EP3692028B1 (en) | 2017-10-06 | 2023-04-26 | Forma Therapeutics, Inc. | Inhibiting ubiquitin specific peptidase 30 |
| US11306089B2 (en) | 2018-01-24 | 2022-04-19 | Life Molecular Imaging Limited | Gamma-carboline compounds for the detection of Tau aggregates |
| EP3743426A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Azacarboline compounds for the detection of tau aggregates |
| US11623927B2 (en) | 2018-03-02 | 2023-04-11 | The Trustees Of The University Of Pennsylvania | Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules |
| MX2020012180A (es) | 2018-05-17 | 2021-01-29 | Forma Therapeutics Inc | Compuestos biciclicos fusionados utiles como inhibidores de la peptidasa 30 especifica de ubiquitina. |
| WO2020041331A1 (en) | 2018-08-20 | 2020-02-27 | Arvinas Operations, Inc. | Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases |
| EP3853234B1 (en) | 2018-09-18 | 2025-04-23 | Nikang Therapeutics, Inc. | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
| US11535618B2 (en) | 2018-10-05 | 2022-12-27 | Forma Therapeutics, Inc. | Fused pyrrolines which act as ubiquitin-specific protease 30 (USP30) inhibitors |
| BR112021006488A2 (pt) | 2018-10-05 | 2021-07-06 | Annapurna Bio Inc | compostos e composições para o tratamento de condições associadas com atividade do receptor apj |
| TWI767148B (zh) | 2018-10-10 | 2022-06-11 | 美商弗瑪治療公司 | 抑制脂肪酸合成酶(fasn) |
| JP7119978B2 (ja) * | 2018-12-20 | 2022-08-17 | オムロン株式会社 | 制御装置およびプログラム |
| EP3966216A1 (en) * | 2019-05-09 | 2022-03-16 | F. Hoffmann-La Roche AG | Regio-selective synthesis of imidazo[1,2-a]pyrimidines |
| WO2021011913A1 (en) | 2019-07-17 | 2021-01-21 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
| CN113526526A (zh) * | 2021-07-12 | 2021-10-22 | 苏州大学 | 氘代氨制备方法及以其作为氘源参与的氘代反应 |
| JP2024534151A (ja) | 2021-08-27 | 2024-09-18 | ジェネンテック， インコーポレイテッド | タウ病態の治療方法 |
| WO2023245008A1 (en) | 2022-06-13 | 2023-12-21 | Genentech, Inc. | Methods of delaying or preventing the onset of alzheimer's disease using crenezumab |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE76515C (de) | F. MORA in Mailand | Verfahren zur Herstellung imitirter Ledertapete aus Baumwollstoff | ||
| DD76515A (es) * | ||||
| EP1340759A1 (en) | 2002-02-28 | 2003-09-03 | Sanofi-Synthelabo | 1-[alkyl], 1-[(heteroaryl)alkyl] and 1-[(aryl)alkyl]-7-(pyrimidin-4-yl)-imidazo[1,2-a]pyrimidin-5(1H)-one derivatives |
| US6875784B2 (en) | 2002-10-09 | 2005-04-05 | Pharmacia & Upjohn Company | Antimibicrobial [3.1.0.] bicyclic oxazolidinone derivatives |
| SI1999109T1 (sl) | 2006-03-30 | 2012-04-30 | Univ Pennsylvania | Derivati stirilpiridina in njihova uporaba za vezavo in prikazovanje amiloidnih plakov |
| CN101855218A (zh) * | 2007-09-13 | 2010-10-06 | 康塞特医药品有限公司 | 氘化的儿茶酚和苯并[d][1,3]间二氧杂环戊烯及其衍生物的合成 |
| US8932557B2 (en) | 2008-02-14 | 2015-01-13 | Eli Lilly And Company | Imaging agents for detecting neurological dysfunction |
| ES2907992T5 (en) | 2008-02-14 | 2025-03-19 | Lilly Co Eli | Novel imaging agents for detecting neurological dysfunction |
| US20100144657A1 (en) * | 2008-12-09 | 2010-06-10 | Auspex Pharmaceuticals, Inc. | PHENYLPIPERIDINE MODULATORS OF mu-OPIOID RECEPTORS |
| US8691187B2 (en) * | 2009-03-23 | 2014-04-08 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| US8491869B2 (en) | 2009-03-23 | 2013-07-23 | Eli Lilly And Company | Imaging agents for detecting neurological disorders |
| EP2450332A1 (en) * | 2010-10-22 | 2012-05-09 | Bayer Pharma Aktiengesellschaft | Compounds for use in Imaging, diagnosing and/or treatment of diseases of the central nervous system (F-D2-Deprenyl) |
| CA2817165A1 (en) * | 2010-11-15 | 2012-05-24 | Patrick Chaltin | Novel antiviral compounds |
| CN107011342A (zh) * | 2012-05-22 | 2017-08-04 | 伊莱利利公司 | 用于检测神经功能障碍的基于咔啉和咔唑的成像剂 |
| JP6194416B2 (ja) * | 2013-10-08 | 2017-09-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | タウ−ｐｅｔリガンドとしてのジアザカルバゾール誘導体 |
| ES2867814T3 (es) | 2014-05-13 | 2021-10-20 | Hoffmann La Roche | Compuestos heterocíclicos deuterados y su uso como agentes de formación de imágenes |
-
2015
- 2015-05-12 ES ES15725253T patent/ES2867814T3/es active Active
- 2015-05-12 LT LTEP15725253.7T patent/LT3143011T/lt unknown
- 2015-05-12 PL PL15725253T patent/PL3143011T3/pl unknown
- 2015-05-12 SG SG11201609281UA patent/SG11201609281UA/en unknown
- 2015-05-12 DK DK15725253.7T patent/DK3143011T3/da active
- 2015-05-12 CN CN201910795177.8A patent/CN110483522B/zh active Active
- 2015-05-12 EP EP15725253.7A patent/EP3143011B1/en active Active
- 2015-05-12 MX MX2016014615A patent/MX376163B/es active IP Right Grant
- 2015-05-12 HR HRP20210641TT patent/HRP20210641T1/hr unknown
- 2015-05-12 AU AU2015261008A patent/AU2015261008B2/en active Active
- 2015-05-12 WO PCT/EP2015/060447 patent/WO2015173225A1/en active Application Filing
- 2015-05-12 CA CA2948721A patent/CA2948721C/en active Active
- 2015-05-12 KR KR1020167034871A patent/KR102530129B1/ko active Active
- 2015-05-12 SG SG10201805628TA patent/SG10201805628TA/en unknown
- 2015-05-12 EP EP21155891.1A patent/EP3901145A1/en active Pending
- 2015-05-12 RU RU2016147742A patent/RU2696492C2/ru active
- 2015-05-12 SI SI201531590T patent/SI3143011T1/sl unknown
- 2015-05-12 CN CN201580025219.XA patent/CN106459059B/zh active Active
- 2015-05-12 JP JP2016567651A patent/JP6529986B2/ja active Active
- 2015-05-12 PT PT157252537T patent/PT3143011T/pt unknown
- 2015-05-12 HU HUE15725253A patent/HUE053939T2/hu unknown
- 2015-05-12 RS RS20210532A patent/RS61810B1/sr unknown
- 2015-05-12 IL IL280791A patent/IL280791B2/en unknown
- 2015-05-12 MX MX2020010847A patent/MX384604B/es unknown
- 2015-05-12 KR KR1020237006997A patent/KR102618139B1/ko active Active
-
2016
- 2016-01-26 US US15/006,997 patent/US10076581B2/en active Active
- 2016-11-01 IL IL248692A patent/IL248692B/en active IP Right Grant
-
2018
- 2018-07-31 US US16/050,453 patent/US10675367B2/en active Active
-
2019
- 2019-05-14 AU AU2019203369A patent/AU2019203369B2/en active Active
- 2019-05-15 JP JP2019091813A patent/JP6681498B2/ja active Active
- 2019-12-22 IL IL271631A patent/IL271631B/en active IP Right Grant
-
2020
- 2020-06-08 US US16/895,352 patent/US11504440B2/en active Active
-
2022
- 2022-11-18 US US18/056,856 patent/US12214058B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016014615A (es) | Compuestos heterociclicos deuterados y su uso como agentes formadores de imagenes. | |
| MX2017009505A (es) | Derivados de 9h-pirrolo-dipiridina. | |
| CO2017003279A2 (es) | Compuestos y composiciones farmacéuticamente aceptables de los mismos, eficaces como inhibidores de mk2 | |
| MX2016013052A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados y su uso como inhibidores irak4. | |
| CY1122177T1 (el) | Δοτες νιτροξυλιου με βελτιωμενο θεραπευτικο δεικτη | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| NI201700034A (es) | Indazoles sustituidos con benzilo como inhibidores de bub1. | |
| BR112018005497A2 (pt) | compostos heterocíclicos e usos dos mesmos | |
| CR20170116A (es) | Compuestos que inhiben la proteina mcl-1 | |
| UY37098A (es) | Moduladores de ror-gamma | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| MX360495B (es) | Derivados deuterados de ruxolitinib. | |
| MX2018005725A (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cancer. | |
| DOP2018000062A (es) | Piridinona dicaboxamidas para uso como inhibidores de bromodominio | |
| UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
| NI201500096A (es) | Compuesto químicos | |
| MX2017000183A (es) | Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides. | |
| DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
| CR20160565A (es) | Derivados de naftiridinadiona | |
| MX2016000219A (es) | Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos. | |
| CR20160039A (es) | Imidazotiazol sulfonamidas como nematicidas | |
| MX2019007950A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa. | |
| DOP2016000325A (es) | Compuestos, composición farmacéutica y su uso en el tratamiento de enfermedades neurodegenerativas | |
| EA201892157A1 (ru) | Фосфаплатиновые жидкие составы | |
| BR112017015455A2 (pt) | agentes de imagiologia pet |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |